Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4
3(75.0%)
N/A
1(25.0%)
4Total
Phase 4(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05193396Phase 4Recruiting

Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment

Role: lead

NCT04254354Recruiting

Transgender Men, Non-binary Persons and Testosterone Treatment BODY IDENTITY CLINIC

Role: lead

NCT02509702Not ApplicableCompleted

Use of SMSs to Improve Attendance to Cervical Cancer Follow-up Screening

Role: lead

NCT02433730Phase 4Completed

Testosterone Therapy in Hypogonadal Men Treated With Opioids

Role: lead

NCT01560546Phase 4Completed

Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM)

Role: lead

All 5 trials loaded